• Sanofi plans a US regulatory filing in H2 2026 to extend Nexviazyme’s label to infantile-onset Pompe disease.
• Data disclosure scheduled for July 8, 2026 at the International Congress on Neuromuscular Diseases in Florence.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sanofi SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-296990), on July 07, 2026, and is solely responsible for the information contained therein.